Clinical trial
Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of…
NCT00329693 · Ferring Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00329693 |
|---|---|
| Title | Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide |
| Official title | A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian… |
| Lead sponsor | Ferring Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Hyperstimulation Syndrome |
| Intervention type | Drug |
| Interventions | Norprolac |
| Enrollment | 182 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | May 1, 2008 |
| First posted | May 25, 2006 |
| Last update posted | May 19, 2011 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: